Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2022 · 10-Q
Revenue$8.77M$8.77M+101.1% vs Q1 2021 Net Income-$19.67M-$19.67MN/M vs Q1 2021 EPS Diluted-$0.35-$0.35N/M vs Q1 2021 Operating Income-$17,369,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$18,640,000N/M Margins · derivedOperating margin-198.1%+170.4 pt vs Q1 2021
Net margin-224.4%+137.3 pt vs Q1 2021
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end